Since BBG treatment induced a decrease in microglial M1 markers, it is more likely that the neuroprotective effects of BBG treatment involves P2X7 receptor inhibition rather than P2X4 receptor inhibition in ALS. The gene discussed is P2RX7; the disease is amyotrophic lateral sclerosis.